Pioneering single-cell kidney atlas sheds light on potential treatments

July 25 2024

Comprehensive integrated multimodal human kidney single-cell atlas. a, Overview of the multimodal analysis. b, UMAP of 338,565 cells/nuclei in an integrated human kidney snRNA-seq/scRNA-seq and snATAC–seq data generated in this study. c, UMAP of 588,425 integrated human kidney snRNA-seq/scRNA-seq and snATAC–seq data from the present study and KPMP. Credit: Nature Genetics (2024). DOI: 10.1038/s41588-024-01802-x

Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania revealed the most extensive single cell atlas of the human kidney, capturing the complexity of healthy and diseased kidneys at an unprecedented level and predicting chronic kidney disease (CKD) progression earlier in its
The findings were published July 24 in the journal *Nature Genetics*.

CKD affects more than 1 in 7 U.S. adults—an estimated 37 million Americans, according to the National Institutes of Health (NIH). The risk is even higher for Americans with diabetes or high blood pressure—the two most common causes of CKD.

"CKD is rare in children, but for those affected, it can be a very serious life-altering condition," said Jonathan Levisohn, MD, Ph.D., one of the first authors and a pediatric nephrology fellow in the Division of Nephrology at CHOP. "It is also clear that while CKD most commonly affects older individuals, the risk for developing the disease starts to accrue much earlier, starting during gestation and childhood."

Senior study author Katalin Susztak, MD, Ph.D., emphasized that the findings fill a critical knowledge gap by presenting the first ever roadmap of the human kidneys that includes the analysis of spatial relationship of the cells.

"Human kidneys are intricate three-dimensional structures in the body, but until this research, the spatial and molecular principles of kidney health and disease were not well understood," said Susztak, Co-Leader of the Penn-CHOP Kidney Innovation Center, a research collaboration between CHOP and Penn-Medicine focused on transforming patient care through early detection, prevention and treatment of kidney disease and its complications across the lifespan.

"We now have a powerful tool for prognosis, outperforming traditional histopathological analysis especially in early-stage kidney disease."

In the study, Susztak and her team analyzed more than 700,000 cells.
from 81 kidney samples in patients from ages 24 to 90. The researchers used machine learning to develop the high-resolution atlas, allowing them to integrate multi-omics data, map cellular and spatial information, identify tissue microenvironments and develop predictive models for kidney disease progression.

Key findings include identification of 44 main and 114 distinct cell sub-types or states in both healthy and CKD-affected human kidneys. The researchers identified four distinct spatial microenvironments based on gene expression: glomerular, immune, tubule and fibrotic.

Fibrosis is a common manifestation across all forms of progressive CKD with most prior studies focusing on its predictive ability in severe cases. Glomerular filtration rate (GFR) and albuminuria predict kidney function decline reasonably well in advanced CKD, but prognosis is challenging in earlier disease stages.

In this study, however, data revealed a gene signature in the fibrotic microenvironment (FME-GS), that can classify kidney samples and predict future kidney function decline.

The team plans to further define the fibrotic microenvironment, validate its predictive power in additional cohorts and understand the underlying mechanisms. They aim to explore therapeutic targets within the fibrotic microenvironment, potentially paving the way for new treatments to halt or reverse kidney fibrosis.

"Although foundational, we envision the clinical implications of this study to be potentially profound, as this new understanding can lead to better diagnostics and precision treatments for patients with chronic kidney disease," said Susztak, who is also a Professor of Medicine at Penn.

Provided by Children's Hospital of Philadelphia


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.